These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 22384806)
1. Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice. Wang F; Wang Z; Tian H; Qi M; Zhai Z; Li S; Li R; Zhang H; Wang W; Fu S; Lu J; Rodriguez R; Guo Y; Zhou L Curr Gene Ther; 2012 Apr; 12(2):67-76. PubMed ID: 22384806 [TBL] [Abstract][Full Text] [Related]
2. Teratogenic Toxicity Evaluation of Bladder Cancer-Specific Oncolytic Adenovirus on Mice. Lu K; Wang F; Ma B; Cao W; Guo Q; Wang H; Rodriguez R; Wang Z Curr Gene Ther; 2021; 21(2):160-166. PubMed ID: 33334289 [TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer. Zhai Z; Wang Z; Fu S; Lu J; Wang F; Li R; Zhang H; Li S; Hou Z; Wang H; Rodriguez R Gene Ther; 2012 Nov; 19(11):1065-74. PubMed ID: 22218302 [TBL] [Abstract][Full Text] [Related]
4. Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro. Wang L; Zhang Y; Zhao J; Xiao E; Lu J; Fu S; Wang Z Tumour Biol; 2014 Nov; 35(11):10879-90. PubMed ID: 25085582 [TBL] [Abstract][Full Text] [Related]
5. Construction of urothelium-specific recombinant adenovirus and its inhibition in bladder cancer cell. He XD; Wang ZP; Wei HY; Zhou Q; Wang DG; Tian JQ; Fu SJ; Rodriguez R Urol Int; 2009; 82(2):209-13. PubMed ID: 19322012 [TBL] [Abstract][Full Text] [Related]
6. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy. Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050 [TBL] [Abstract][Full Text] [Related]
7. Effect of combined treatment of radiation and tissue-specific recombinant oncolytic adenovirus on bladder cancer cells. Zhang H; Wang F; Mao C; Zhang Z; Fu S; Lu J; Zhai Z; Li R; Li S; Rodriguez R; Wang Z Int J Radiat Biol; 2017 Feb; 93(2):174-183. PubMed ID: 27600610 [TBL] [Abstract][Full Text] [Related]
8. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus. Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150 [TBL] [Abstract][Full Text] [Related]
9. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression. Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827 [TBL] [Abstract][Full Text] [Related]
10. Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses. Rojas JJ; Guedan S; Searle PF; Martinez-Quintanilla J; Gil-Hoyos R; Alcayaga-Miranda F; Cascallo M; Alemany R Mol Ther; 2010 Nov; 18(11):1960-71. PubMed ID: 20808288 [TBL] [Abstract][Full Text] [Related]
11. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells. Fuerer C; Homicsko K; Lukashev AN; Pittet AL; Iggo RD BMC Cancer; 2006 Oct; 6():236. PubMed ID: 17020613 [TBL] [Abstract][Full Text] [Related]
12. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth. He G; Lei W; Wang S; Xiao R; Guo K; Xia Y; Zhou X; Zhang K; Liu X; Wang Y J Cancer Res Clin Oncol; 2012 Apr; 138(4):657-70. PubMed ID: 22237452 [TBL] [Abstract][Full Text] [Related]
13. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity. Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462 [TBL] [Abstract][Full Text] [Related]
14. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression. Zhang KJ; Zhang J; Wu YM; Qian J; Liu XJ; Yan LC; Zhou XM; Xiao RJ; Wang YG; Cao X; Wei N; Liu XR; Tang B; Jiao XY; Chen K; Liu XY Cancer Gene Ther; 2012 Sep; 19(9):619-29. PubMed ID: 22790965 [TBL] [Abstract][Full Text] [Related]
15. Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model. Lei W; Liu HB; Wang SB; Zhou XM; Zheng SD; Guo KN; Ma BY; Xia YL; Tan WS; Liu XY; Wang YG Acta Pharmacol Sin; 2013 Apr; 34(4):531-40. PubMed ID: 23503473 [TBL] [Abstract][Full Text] [Related]
16. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT. Doloff JC; Jounaidi Y; Waxman DJ Cancer Gene Ther; 2011 Mar; 18(3):153-66. PubMed ID: 20865021 [TBL] [Abstract][Full Text] [Related]
17. Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth. Li Y; Zhang B; Zhang H; Zhu X; Feng D; Zhang D; Zhuo B; Li L; Zheng J J Cancer Res Clin Oncol; 2013 Jun; 139(6):933-41. PubMed ID: 23443256 [TBL] [Abstract][Full Text] [Related]
18. A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression. Cao W; Tian J; Li C; Gao Y; Liu X; Lu J; Wang Y; Wang Z; Svatek RS; Rodriguez R Virol J; 2017 Aug; 14(1):149. PubMed ID: 28789701 [TBL] [Abstract][Full Text] [Related]
19. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models. Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142 [TBL] [Abstract][Full Text] [Related]
20. Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. Zhang J; Ramesh N; Chen Y; Li Y; Dilley J; Working P; Yu DC Cancer Res; 2002 Jul; 62(13):3743-50. PubMed ID: 12097284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]